# Clinical Cases: GI Pharmacology

## Case 1: GERD Refractory to PPI Therapy

### Patient Demographics
- **Age:** 52 years
- **Sex:** Male
- **Occupation:** Restaurant manager

### Chief Complaint
"My heartburn is still bothering me even though I take my acid pill every day."

### History of Present Illness
A 52-year-old man with a 5-year history of gastroesophageal reflux disease (GERD) presents with persistent symptoms despite taking omeprazole 20 mg daily for 3 years. He describes daily heartburn, regurgitation (especially when lying down), and occasional nocturnal awakening with acid in his throat. Symptoms are worse after large meals, spicy foods, and alcohol. He takes his omeprazole "whenever he remembers," often with breakfast. He denies dysphagia, odynophagia, weight loss, or GI bleeding. He has gained 20 pounds over the past 2 years and notes his symptoms have worsened with weight gain. He also takes ibuprofen 400 mg 2-3 times weekly for knee pain.

### Past Medical History
- GERD (5 years)
- Osteoarthritis of knees
- Obesity (BMI 32)
- Hyperlipidemia

### Social History
- Alcohol: 2-3 beers nightly
- Tobacco: Former smoker (quit 10 years ago, 15 pack-year history)
- Coffee: 4 cups daily

### Physical Examination
- **Vital Signs:** BP 138/82 mmHg, HR 78 bpm, BMI 32
- **General:** Obese male, no distress
- **HEENT:** Normal oropharynx, no dental erosions visible
- **Chest:** Clear lungs
- **Abdomen:** Soft, obese, mild epigastric tenderness, no masses
- **Cardiac:** Regular rhythm

### Workup
- **EGD:** LA Grade B esophagitis (mucosal breaks > 5mm, not circumferential); no Barrett's esophagus; no stricture; negative H. pylori biopsies
- **Esophageal pH monitoring (off PPI):** DeMeester score 48 (abnormal > 14.7); acid exposure time 9.2% (abnormal > 4.2%)

### Assessment
**Refractory GERD with erosive esophagitis** due to:
1. Suboptimal PPI dosing and timing
2. Lifestyle factors (obesity, alcohol, large meals, late eating)
3. NSAID use
4. Ongoing esophageal acid exposure despite PPI

### Treatment Plan

**OPTIMIZE PPI THERAPY:**
1. **Switch to twice-daily PPI:** Omeprazole 20 mg or pantoprazole 40 mg twice daily
2. **Correct timing:** Take 30-60 minutes BEFORE breakfast and dinner (PPIs require food-stimulated acid secretion to be activated)
3. **Consider PPI switch:** Some patients respond better to different PPIs (pantoprazole, esomeprazole, or rabeprazole)

**MECHANISM REVIEW - Why PPI Timing Matters:**
- PPIs are prodrugs that require acid activation
- They irreversibly inhibit the H+/K+-ATPase (proton pump) on parietal cells
- Proton pumps are active only when parietal cells are stimulated (by food)
- Taking PPI before meals ensures drug is present when pumps are active
- 70% of pumps are inhibited with optimal dosing; maximal effect takes 3-5 days

**ADJUNCTIVE MEDICATIONS:**
1. **Add H2 blocker at bedtime:** Famotidine 20-40 mg at bedtime for nocturnal breakthrough
   - H2 blockers work faster but tolerance develops
   - Useful for nocturnal symptoms not controlled by PPI
2. **Consider adding alginate-antacid:** Gaviscon after meals and at bedtime
   - Creates a physical barrier (raft) on gastric contents
   - Particularly useful for postprandial and nocturnal reflux

**LIFESTYLE MODIFICATIONS (Critical):**
1. **Weight loss:** Target 5-10% body weight reduction
2. **Dietary changes:**
   - Avoid trigger foods (fatty foods, chocolate, peppermint, caffeine)
   - Reduce coffee to 1-2 cups daily
   - Limit alcohol
   - Smaller, more frequent meals
3. **Timing modifications:**
   - No eating within 3 hours of bedtime
   - Elevate head of bed 6-8 inches
4. **Stop NSAID:** Switch to acetaminophen for pain; if NSAID necessary, add PPI protection

**MEDICATION CONSIDERATIONS:**
- **Discontinue ibuprofen:** NSAIDs impair mucosal defense and worsen reflux injury
- If patient requires chronic NSAID, ensure continuous PPI therapy

**IF REFRACTORY AFTER OPTIMIZATION:**
- Consider adding baclofen 10 mg TID (reduces transient lower esophageal sphincter relaxations)
- Surgical consultation for fundoplication if lifestyle and maximal medical therapy fail

### Follow-up
- Reassess symptoms in 8 weeks
- Repeat EGD in 8-12 weeks to confirm healing of esophagitis
- If healed, attempt to step down to once-daily PPI
- Long-term PPI use considerations: monitor B12, magnesium; bone health (though evidence weak)

### Clinical Pearl
PPI failure is often due to incorrect dosing, timing, or poor adherence rather than true refractory disease. Before escalating therapy, ensure the patient takes the PPI 30-60 minutes before a meal (not at bedtime or with food) and addresses lifestyle factors. True refractory GERD (persistent symptoms despite twice-daily PPI with correct timing) should prompt evaluation for alternative diagnoses including functional heartburn, eosinophilic esophagitis, or achalasia. Adding an H2 blocker at bedtime can help nocturnal breakthrough but tolerance may develop. Weight loss is the lifestyle modification with the best evidence for GERD improvement.

### Clinical Image
![Esophagitis Endoscopy](case_01_image.jpg)

*Endoscopic image demonstrating erosive esophagitis with mucosal breaks in the distal esophagus, characteristic of GERD. Proper PPI therapy with correct timing should lead to mucosal healing in most patients.*

**Image Source:** Wikimedia Commons - "Peptic esophagitis"
**License:** CC BY-SA 3.0
**URL:** https://commons.wikimedia.org/wiki/File:Peptic_esophagitis.jpg

---

## Case 2: Opioid-Induced Constipation Management

### Patient Demographics
- **Age:** 67 years
- **Sex:** Female
- **Occupation:** Retired teacher

### Chief Complaint
"I haven't had a bowel movement in 6 days and my stomach is so bloated."

### History of Present Illness
A 67-year-old woman with metastatic breast cancer to bone presents with severe constipation. She was started on extended-release morphine 30 mg twice daily 3 weeks ago for pain control from bony metastases. Since starting opioids, she has had progressively worsening constipation. She previously had daily bowel movements but now has a bowel movement only every 5-7 days despite taking docusate 100 mg twice daily. She describes hard, pellet-like stools requiring significant straining. She has abdominal bloating, cramping, decreased appetite, and nausea. She tried senna but found the cramping intolerable. Her pain is well-controlled on the current morphine dose. She drinks about 4 glasses of water daily and has limited mobility due to bone pain.

### Past Medical History
- Metastatic breast cancer (bone metastases to spine, ribs, pelvis)
- Hypertension
- Type 2 diabetes
- Osteoporosis

### Medications
- Morphine ER 30 mg BID
- Morphine IR 15 mg PRN breakthrough pain
- Docusate 100 mg BID
- Metformin 1000 mg BID
- Lisinopril 10 mg daily
- Ondansetron 4 mg PRN nausea

### Physical Examination
- **Vital Signs:** BP 142/78 mmHg, HR 82 bpm, afebrile
- **General:** Thin female, mild distress from abdominal discomfort
- **Abdomen:** Distended, tympanitic, diffusely tender, no rebound/guarding; decreased bowel sounds; no palpable masses
- **Rectal:** Hard stool in vault, no masses, no blood

### Workup
- **Abdominal X-ray:** Significant stool burden throughout colon, no obstruction, no free air
- **BMP:** Normal (rules out hypercalcemia, hypokalemia)
- **TSH:** Normal

### Diagnosis
**Opioid-Induced Constipation (OIC)** - Rome IV criteria met:
- New or worsening constipation when initiating, changing, or increasing opioid therapy
- Includes reduced bowel movement frequency, straining, hard stools, sensation of incomplete evacuation

### Pathophysiology of OIC
Opioids cause constipation through multiple mechanisms via mu-opioid receptors in the gut:
1. **Decreased peristalsis:** Reduced propulsive contractions
2. **Increased water absorption:** Prolonged intestinal transit allows more fluid reabsorption
3. **Increased sphincter tone:** Reduced relaxation of anal sphincter
4. **Reduced secretions:** Decreased fluid secretion into bowel lumen

Unlike most opioid side effects, **tolerance to constipation does NOT develop** - patients require ongoing bowel management.

### Treatment Plan

**ACUTE MANAGEMENT (Disimpaction):**
1. **Rectal interventions first:**
   - Glycerin suppository
   - If ineffective: Bisacodyl suppository
   - Consider mineral oil enema or tap water enema if suppositories fail
2. **Oral osmotic laxative:**
   - Polyethylene glycol (MiraLAX) 17 g in 8 oz water once or twice daily until cleared

**MAINTENANCE BOWEL REGIMEN:**

**Step 1: First-Line Agents (Stimulant + Osmotic)**
1. **Senna** 8.6-17.2 mg at bedtime (stimulant laxative)
   - Works by stimulating colonic motility via myenteric plexus
   - Can start at lower dose and titrate to effect
2. **Polyethylene glycol (PEG)** 17 g daily
   - Osmotic laxative - draws water into bowel
   - Adjust dose based on response (can use 17-34 g daily)

**Why NOT just docusate?**
- Docusate is a stool softener with minimal evidence of efficacy
- Does NOT address the reduced motility caused by opioids
- Should not be used as monotherapy for OIC

**Step 2: If Conventional Laxatives Fail - PAMORA Agents**

**Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs):**
- Block mu-opioid receptors in the GI tract
- Do NOT cross blood-brain barrier - preserve analgesia
- Do NOT precipitate opioid withdrawal

Options:
1. **Methylnaltrexone (Relistor):**
   - Subcutaneous injection 8-12 mg every other day PRN
   - Works within 30-60 minutes
   - Good for acute rescue

2. **Naloxegol (Movantik):**
   - Oral, 25 mg daily on empty stomach
   - Avoid with strong CYP3A4 inhibitors
   - First-line oral PAMORA

3. **Naldemedine (Symproic):**
   - Oral, 0.2 mg daily
   - Can be taken with or without food

**For This Patient:**
- Start senna 8.6 mg BID + PEG 17 g daily
- If no improvement in 72 hours, add naloxegol 25 mg daily
- Discontinue ineffective docusate

**SUPPORTIVE MEASURES:**
1. **Increase fluid intake:** Goal 8 glasses daily
2. **Dietary fiber:** If tolerated (may worsen bloating in some)
3. **Activity:** Encourage mobility as able
4. **Toilet schedule:** Attempt bowel movement 30 minutes after meals

**IMPORTANT COUNSELING:**
- Start bowel regimen when opioid initiated (prevention > treatment)
- Take stimulant laxative prophylactically, not PRN
- OIC will not resolve spontaneously - need ongoing therapy
- If severe cramping with senna, can switch to different stimulant (bisacodyl) or use osmotic alone

### Follow-up
- Phone follow-up in 3-5 days to assess response
- Goal: Bowel movement at least every 2-3 days without straining
- Adjust regimen based on response
- If PAMORAs needed, continue as long as on opioid therapy

### Clinical Pearl
Opioid-induced constipation is the most common opioid side effect and does NOT develop tolerance - it persists throughout opioid therapy. Prevention is key: all patients starting opioids should receive prophylactic bowel regimen (stimulant +/- osmotic laxative). Docusate alone is ineffective for OIC. Conventional laxative failure is common (40-50% of patients), and PAMORAs offer a targeted mechanism-based approach. PAMORAs block peripheral mu-receptors in the gut without affecting central analgesia or causing withdrawal. The ondansetron this patient takes for nausea also has constipating effects (5-HT3 antagonism reduces GI motility) - consider switching to a prokinetic antiemetic if possible.

---